An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Lucitanib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms FINESSE
- Sponsors IRIS; Servier
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2017 This trial has been completed in Belgium (end date: 5 Apr 2017) and Spain.
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.